- Home
- SNTI vs MTEK Comparison
SNTI vs MTEK Comparison
Compare SNTI & MTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- MTEK
- Stock Information
- Founded
- SNTI 2016
- MTEK 2008
- Country
- SNTI United States
- MTEK Israel
- Employees
- SNTI N/A
- MTEK N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- MTEK
- Sector
- SNTI Health Care
- MTEK
- Exchange
- SNTI Nasdaq
- MTEK Nasdaq
- Market Cap
- SNTI 85.3M
- MTEK N/A
- IPO Year
- SNTI N/A
- MTEK 2022
- Fundamental
- Price
- SNTI $1.98
- MTEK $3.46
- Analyst Decision
- SNTI Strong Buy
- MTEK
- Analyst Count
- SNTI 2
- MTEK 0
- Target Price
- SNTI $8.50
- MTEK N/A
- AVG Volume (30 Days)
- SNTI 711.7K
- MTEK 161.0K
- Earning Date
- SNTI 08-12-2025
- MTEK 08-27-2025
- Dividend Yield
- SNTI N/A
- MTEK N/A
- EPS Growth
- SNTI N/A
- MTEK N/A
- EPS
- SNTI N/A
- MTEK N/A
- Revenue
- SNTI N/A
- MTEK $6,078,953.00
- Revenue This Year
- SNTI N/A
- MTEK N/A
- Revenue Next Year
- SNTI $150.00
- MTEK N/A
- P/E Ratio
- SNTI N/A
- MTEK N/A
- Revenue Growth
- SNTI N/A
- MTEK 50.80
- 52 Week Low
- SNTI $1.52
- MTEK $1.48
- 52 Week High
- SNTI $16.94
- MTEK $6.47
- Technical
- Relative Strength Index (RSI)
- SNTI 43.19
- MTEK 65.14
- Support Level
- SNTI $2.10
- MTEK $3.00
- Resistance Level
- SNTI $2.43
- MTEK $3.44
- Average True Range (ATR)
- SNTI 0.18
- MTEK 0.25
- MACD
- SNTI 0.05
- MTEK 0.01
- Stochastic Oscillator
- SNTI 79.25
- MTEK 91.01
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.